Relmada Therapeutics Provides Corporate Update : comparemela

Company Well-Positioned for a Pivotal 2024 with Multiple Key Clinical Development Milestones Anticipated
Relmada's Strong Balance Sheet to Support the Company Through All of 2024's Expected Critical...

Related Keywords

Tim Mccarthy , Cedric Ogorman , Sergio Traversa , Prnewswire Relmada Therapeutics Inc , Corporate Communications , Securities Exchange , Key Clinical Development Milestones , Andrew Cutler As Senior Clinical Development Advisor , Relmada Therapeutics Inc , Nasdaq , Company Well Positioned , Multiple Key Clinical Development Milestones , Strong Balance Sheet , Company Through All , Chief Executive , Chief Medical Officer , Cedrico Gorman , Andrew Cutler , Senior Clinical Development Advisor , Relmada Therapeutics , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Markets ,